AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02007564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIFE Intervention
Description: RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
Study NCT04582110 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography
Description: Each subject underwent Optical coherence tomography angiography (a non-invasive, fast, diagnostic imaging technique)
Study NCT03841734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment
Description: 8 patients will be treat with bosentan at 145 mg per day during 14 days
Study NCT00849108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS747158
Description: dosages at rest and at stress were not to exceed a total of 14 mCi.~Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period.~Cohort 2: Patients to recieve IV bolus injections of BMS747158:~For the Pharmacologic (Adenosine) Stress:~* Doses at rest were to range between 2.9 and 3.4 mCi.~* Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~* Doses at rest were to range between 1.7 and 2.0 mCi.~* Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi.
Study NCT03468894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill desk walking
Description: See intervention arm description
Study NCT02437370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02437370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT00751348 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PriorixTM
Description: Subcutaneous administration in left upper arm
Study NCT00751348 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VarilrixTM
Description: Subcutaneous administration in right upper arm
Study NCT00751348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix-Tetra®
Description: Subcutaneous injection in left upper arm
Study NCT03084588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methadone
Description: Patients will be given methadone at induction of anesthesia
Study NCT03084588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: Patients will be given an interscalene block prior to induction of anesthesia
Study NCT02258100 — intervention group
Intervention type: OTHER
Intervention: Electronic Medical Record
Description: Advent of EMR use for documentation of anesthetic care
Study NCT00006101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eflornithine
Description: Take 500mg of DFMO per day for 12 months
Study NCT00006101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take placebo per day for 12 months
Study NCT03096132 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Based Behavioral Treatment
Description: Treatment includes 20 90 minute visits over 6 months which include 60 min parent and child separate groups and 30 min behavioral coaching. FBT includes information regarding nutrition and physical activity, as well as behavior therapy skills, including parenting skills, self-monitoring, problem solving skills, motivation systems, emotional regulation, stress management, stimulus control, and relapse prevention.
Study NCT03096132 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help Fam. Based Bx Treatment
Description: Treatment includes 14 20 minute visits over 6 months. gshFBT is delivered to parent/child dyads and includes the same content in the FBT groups but it is provided in a manual. The 20-minute visits focus on clarifying information in the manuals, collecting weight and self-monitoring logs, and problem solving any barriers to implementation.
Study NCT03652610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)
Description: Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
Study NCT03652610 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed GSK MenACWY vaccine (Menveo)
Description: Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
Study NCT02648841 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Concurrent Chemo-radiotherapy
Description: Adjuvant concurrent chemo-radiotherapy will be given to the patients in the Experimental group after 4-6 cycles of SOX chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral.
Study NCT02648841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy for active comparator group
Description: 8 cycles of SOX adjuvant chemotherapy will be given to the patients in the active comparator group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
Study NCT02648841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for experimental group
Description: 6 cycles of SOX adjuvant chemotherapy will be given to the patients in the experimental group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
Study NCT02131454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhalation technique training
Description: Training in inhalation technique in asthmatics and COPD patients
Study NCT02613052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 10 mL of normal saline agitated prior to IV administration
Study NCT02613052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human albumin
Description: 10 mL of 5% albumin agitated prior to IV administration
Study NCT02613052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human albumin and propofol
Description: 7 mL of 5% albumin mixed with 3 mL of propofol (10 mg/mL) agitated together prior to IV administration
Study NCT02815345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rhinometry
Description: An acoustic rhinometry device will be used to evaluate the area and the volume of the nasal cavities. Both nasal cavities will be measured except for patients with nasogastric tube.
Study NCT03776565 — intervention group
Intervention type: OTHER
Intervention: Ultrasound
Description: Ultrasound of antrum of stomach
Study NCT02006641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, matching placebo capsules, orally
Study NCT02006641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine
Description: Once daily, encapsulated tablets, orally
Study NCT02735551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Long Acting Reversible Contraception (LARC)
Description: Same day LARC placement (intervention) of Mirena, Skyla, Paragard, Implanon
Study NCT02735551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral for Long Acting Reversible Contraception (LARC)
Description: Referral to local clinic for LARC placement of choice (Mirena, Skyla, Paragard, Implanon, etc.)
Study NCT02437370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT03206190 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture and blood draw
Description: Biomaterial will be collected (not obligate) to compare e.g. Nfl levels in serum and CSF
Study NCT02735551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prescription for Short-Acting Hormonal Contraception
Description: Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice
Study NCT03165110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Onyx BG Meter / App System
Description: Subjects with diabetes used the Onyx BG Meter / App System at home and assessed the features of the App.
Study NCT02846207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqi huoxue
Description: Buyang Huanwu demolition, which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
Study NCT02846207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqi group
Description: Astragalus 60g.Oral administration, twice one day, for 12weeks.
Study NCT02846207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huoxue group
Description: Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
Study NCT02846207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dextrin,oral administration, twice one day, for 12weeks.
Study NCT04017299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHOISIR
Description: Every patient will evaluate each device after 15 minutes of distraction once or twice a day according to the patient's wishes.
Study NCT04017299 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: CHOISIR
Description: Every patient will evaluate each device after 15 minutes of distraction once or twice a day according to the patient's wishes.
Study NCT00696241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and olmesartan
Description: Azilsartan medoxomil 20 mg, tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
Study NCT00696241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and olmesartan
Description: Azilsartan medoxomil 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
Study NCT00696241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and olmesartan
Description: Azilsartan medoxomil 80 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
Study NCT00696241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: Olmesartan 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
Study NCT00696241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.
Study NCT02730663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Niti-S SPAXUS Stent
Description: Endoscopic Ultrasound-Guided Transluminal drainage
Study NCT03447743 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: XR-NTX community location
Description: XR-NTX will be administered at the local health care clinic
Study NCT03690609 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CytoQuel
Description: 3 capsules daily.
Study NCT03690609 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CytoQuel
Description: 2 capsules twice daily.
Study NCT01048385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 concomitant treatment
Description: Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment
Study NCT01048385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treated with capsules containing the vehicle (Sesame oil).
Study NCT02705729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ketac Universal
Description: High-viscous glass ionomer restorative material used as posterior dental filling. This material does not require a dentin conditioning step.
Study NCT02705729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ketac Molar Quick
Description: High-viscous glass ionomer restorative material used as posterior dental filling. This material requires a dentin conditioning step.
Study NCT02279732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT02726074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Study NCT02279732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT03480009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan Hydrobromide
Description: Dextromethorphan capsule
Study NCT03901092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flortaucipir F 18
Description: No study drug will be administered.
Study NCT02123446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: Administered orally.
Study NCT02123446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cephalexin
Description: Administered orally.
Study NCT01318031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1
Description: Subjects will receive a single 45 mg dose of PF-00299804 on Day 1 of Period 1.
Study NCT01318031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2
Description: Subjects will receive a single 30 mg tablet of paroxetine once daily for 3 days (Days 1 to 3). Then, subjects will be co-administered a 45 mg single dose of PF-00299804 plus a single dose of 30 mg paroxetine on Day 4. Single 30 mg doses of paroxetine will be administered once daily for 6 days (Days 5-10).
Study NCT01912378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT01912378 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Study NCT03396614 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CTTC scan, cardiac MRI, ECG, 6 minute walking test, echocardiogram
Description: CTTC scan, cardiac MRI, ECG, 6 minute walking test, echocardiogram
Study NCT02375191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Study NCT03206190 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI will be used to reveal presymptomatic brain morphology changes (not obligate)
Study NCT02375191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Study NCT02422797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG 50 mg
Description: Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.
Study NCT02422797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV 25 mg
Description: Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.~Participants who successfully completed 148 weeks of treatment were given the opportunity to continue to receive DTG + RPV once daily in the Continuation Phase (after Week 148), one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV.
Study NCT02422797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAR
Description: CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI.
Study NCT01708668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Study NCT01708668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined spinal-epidural analgesia
Study NCT01708668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous epidural infusion
Study NCT03480009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
Description: Placebo capsule
Study NCT03480009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.
Study NCT03480009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.
Study NCT01345682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Once daily
Study NCT01345682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Weekly
Study NCT03197909 — intervention group
Intervention type: OTHER
Intervention: Determination of pro-inflammatory plasma factors
Description: Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old
Study NCT02886559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide plus DCAG regimen
Description: chidamide, decitabine, aclarubicin, cytarabine and G-CSF
Study NCT04672421 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medicurtain®
Description: Anti-adhesion barrier (Medicurtain® 5ml prefilled syringe after laparoscopic surgery)
Study NCT04672421 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: No device after laparoscopic surgery
Study NCT02986815 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]Acetate Brain Imaging
Description: Patients will be imaged on a Siemens Biograph 64 slice PET CT scanner. After placing the patient on the scanner and securing the head in a head restraint, a low dose CT of the brain will be acquired. Images with 3 mm slice thickness and spaced at 1.5 mm intervals will be reconstructed in a 300 mm field of view. The purpose of the CT is for image localization and attenuation correction and it is not considered to be a diagnostic quality CT. Following the completion of the CT, the \[11C\]Acetate will be administered. A dynamic PET image will be acquired in 3D list mode for a total of 30 minutes.
Study NCT00507273 — intervention group
Intervention type: OTHER
Intervention: GIST Registry
Description: Internet based data registry about how different physicians treat and manage patients with gastrointestinal stromal tumors.
Study NCT00958217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy-Modified (CPT-M)
Description: Psychotherapy that focuses on thoughts associated with traumatic experiences with the goal of developing skills to reduce trauma-related symptoms. We have modified this therapy to include substance relapse prevention skills, reduce depression and substance relapse. CPT-M was delivered in individual 1-hour sessions once weekly.
Study NCT00958217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Cognitive Behavioral Therapy (ICBT)
Description: Psychotherapy that focuses on thoughts and behaviors associated with depression with the goal of developing skills to reduce depression symptoms. We have integrated substance relapse prevention skills. ICBT was delivered in individual 1-hour sessions once weekly.
Study NCT00510978 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium infantis 35624
Description: 1 sachet/day for one year
Study NCT00510978 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus salivarius UCC118
Description: 1 sachet per day for 1 year
Study NCT00510978 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet per day for 1 year
Study NCT01949519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycopene and Docetaxel
Description: During administration of standard of care Docetaxel at 75 mg/m2 on day 15 and every 21 days, study patients will also receive Lycopene at the dose specified per the dose cohort they are enrolled. There are three dose cohort levels as follows: Dose level 1 = 30 mg PO every day; Dose level 2 = 90 mg PO every day; Dose level 3 = 150 mg PO every day.Treatment will continue until disease progression or toxicity or patient withdrawal.